RPRX Quote, Financials, Valuation and Earnings

Incyte Corp. has a net margin of 57.24% compared to Royalty Pharma Plc's net margin of 19.86%. Royalty Pharma Plc's return on equity of 13.52% beat Incyte Corp.'s return on equity of 30.48%.

Royalty Pharma Plc has a consensus price target of $51.00, signalling upside risk potential of 10.37%. On the other hand Incyte Corp. has an analysts' consensus of $107.09 which suggests that it could grow by 5.75%. Given that Royalty Pharma Plc has higher upside potential than Incyte Corp., analysts believe Royalty Pharma Plc is more attractive than Incyte Corp..

Royalty Pharma Plc has a beta of 0.423, which suggesting that the stock is 57.722% less volatile than S&P 500. In comparison Incyte Corp. has a beta of 0.825, suggesting its less volatile than the S&P 500 by 17.542%.

Royalty Pharma Plc has a quarterly dividend of $0.24 per share corresponding to a yield of 1.94%. Incyte Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Royalty Pharma Plc pays 49.4% of its earnings as a dividend. Incyte Corp. pays out -- of its earnings as a dividend. Royalty Pharma Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Royalty Pharma Plc quarterly revenues are $622M, which are smaller than Incyte Corp. quarterly revenues of $1.5B. Royalty Pharma Plc's net income of $356M is higher than Incyte Corp.'s net income of $299.3M. Notably, Royalty Pharma Plc's price-to-earnings ratio is 25.95x while Incyte Corp.'s PE ratio is 15.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Royalty Pharma Plc is 10.34x versus 3.96x for Incyte Corp.. Usually stocks with elevated PS ratios are considered overvalued.

PTC Therapeutics, Inc. has a net margin of 57.24% compared to Royalty Pharma Plc's net margin of -81.96%. Royalty Pharma Plc's return on equity of 13.52% beat PTC Therapeutics, Inc.'s return on equity of --.

Royalty Pharma Plc has a consensus price target of $51.00, signalling upside risk potential of 10.37%. On the other hand PTC Therapeutics, Inc. has an analysts' consensus of $87.57 which suggests that it could grow by 28.42%. Given that PTC Therapeutics, Inc. has higher upside potential than Royalty Pharma Plc, analysts believe PTC Therapeutics, Inc. is more attractive than Royalty Pharma Plc.

Royalty Pharma Plc has a beta of 0.423, which suggesting that the stock is 57.722% less volatile than S&P 500. In comparison PTC Therapeutics, Inc. has a beta of 0.484, suggesting its less volatile than the S&P 500 by 51.641%.

Royalty Pharma Plc has a quarterly dividend of $0.24 per share corresponding to a yield of 1.94%. PTC Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Royalty Pharma Plc pays 49.4% of its earnings as a dividend. PTC Therapeutics, Inc. pays out -- of its earnings as a dividend. Royalty Pharma Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Royalty Pharma Plc quarterly revenues are $622M, which are larger than PTC Therapeutics, Inc. quarterly revenues of $164.7M. Royalty Pharma Plc's net income of $356M is higher than PTC Therapeutics, Inc.'s net income of -$135M. Notably, Royalty Pharma Plc's price-to-earnings ratio is 25.95x while PTC Therapeutics, Inc.'s PE ratio is 8.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Royalty Pharma Plc is 10.34x versus 3.27x for PTC Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Veru, Inc. has a net margin of 57.24% compared to Royalty Pharma Plc's net margin of -128.15%. Royalty Pharma Plc's return on equity of 13.52% beat Veru, Inc.'s return on equity of -81.05%.

Royalty Pharma Plc has a consensus price target of $51.00, signalling upside risk potential of 10.37%. On the other hand Veru, Inc. has an analysts' consensus of $25.00 which suggests that it could grow by 868.99%. Given that Veru, Inc. has higher upside potential than Royalty Pharma Plc, analysts believe Veru, Inc. is more attractive than Royalty Pharma Plc.

Royalty Pharma Plc has a beta of 0.423, which suggesting that the stock is 57.722% less volatile than S&P 500. In comparison Veru, Inc. has a beta of -1.420, suggesting its less volatile than the S&P 500 by 241.952%.

Royalty Pharma Plc has a quarterly dividend of $0.24 per share corresponding to a yield of 1.94%. Veru, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Royalty Pharma Plc pays 49.4% of its earnings as a dividend. Veru, Inc. pays out -- of its earnings as a dividend. Royalty Pharma Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Royalty Pharma Plc quarterly revenues are $622M, which are larger than Veru, Inc. quarterly revenues of --. Royalty Pharma Plc's net income of $356M is higher than Veru, Inc.'s net income of -$5.3M. Notably, Royalty Pharma Plc's price-to-earnings ratio is 25.95x while Veru, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Royalty Pharma Plc is 10.34x versus 38.01x for Veru, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals, Inc. has a net margin of 57.24% compared to Royalty Pharma Plc's net margin of 36.91%. Royalty Pharma Plc's return on equity of 13.52% beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.97%.

Royalty Pharma Plc has a consensus price target of $51.00, signalling upside risk potential of 10.37%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $532.96 which suggests that it could grow by 7.27%. Given that Royalty Pharma Plc has higher upside potential than Vertex Pharmaceuticals, Inc., analysts believe Royalty Pharma Plc is more attractive than Vertex Pharmaceuticals, Inc..

Royalty Pharma Plc has a beta of 0.423, which suggesting that the stock is 57.722% less volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.303, suggesting its less volatile than the S&P 500 by 69.725%.

Royalty Pharma Plc has a quarterly dividend of $0.24 per share corresponding to a yield of 1.94%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Royalty Pharma Plc pays 49.4% of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. Royalty Pharma Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Royalty Pharma Plc quarterly revenues are $622M, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.2B. Royalty Pharma Plc's net income of $356M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.2B. Notably, Royalty Pharma Plc's price-to-earnings ratio is 25.95x while Vertex Pharmaceuticals, Inc.'s PE ratio is 32.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Royalty Pharma Plc is 10.34x versus 10.62x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.